Insider · CIK 0002131863
Joshua Benjamin Bergmann
Files at GYRE (GYRE THERAPEUTICS, INC.). First filing -, latest -.
In brief
Joshua Benjamin Bergmann files SEC Form 4 as officer at GYRE (GYRE THERAPEUTICS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Joshua Benjamin Bergmann has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 8, 2026 | GYRE GYRE THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jun 10, 2026 |
Questions about Joshua Benjamin Bergmann
Answered from the filings on this page, as of the latest one.
Is Joshua Benjamin Bergmann buying or selling?
Joshua Benjamin Bergmann has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Joshua Benjamin Bergmann's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Joshua Benjamin Bergmann has 0.
Where does Joshua Benjamin Bergmann file Form 4?
Joshua Benjamin Bergmann has filed Form 4 at GYRE (GYRE THERAPEUTICS, INC.) as GC and Corporate Secretary. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.